IDEAYA Biosciences, Inc. (IDYA)
| Market Cap | 3.04B +12.4% |
| Revenue (ttm) | 36.54M -83.0% |
| Net Income | -420.01M |
| EPS | -4.52 |
| Shares Out | 96.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 615,932 |
| Open | 32.07 |
| Previous Close | 32.72 |
| Day's Range | 31.43 - 32.51 |
| 52-Week Range | 26.81 - 42.68 |
| Beta | 0.08 |
| Analysts | Strong Buy |
| Price Target | 50.69 (+60.97%) |
| Earnings Date | Nov 3, 2026 |
About IDYA
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhib... [Read more]
Financial Performance
In 2025, IDEAYA Biosciences's revenue was $218.71 million, an increase of 3024.43% compared to the previous year's $7.00 million. Losses were -$113.70 million, -58.58% less than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price target is $50.69, which is an increase of 60.97% from the latest price.
News
Ideaya Biosciences price target lowered to $39 from $44 at Mizuho
Mizuho lowered the firm’s price target on Ideaya Biosciences (IDYA) to $39 from $44 and keeps an Outperform rating on the shares following the Q3 report.
Ideaya Biosciences price target raised to $66 from $65 at Citi
Citi raised the firm’s price target on Ideaya Biosciences (IDYA) to $66 from $65 and keeps a Buy rating on the shares.
Ideaya Biosciences price target lowered to $45 from $48 at RBC Capital
RBC Capital lowered the firm’s price target on Ideaya Biosciences (IDYA) to $45 from $48 and keeps an Outperform rating on the shares after its Q3 results. All programs continue…
Ideaya Biosciences price target raised to $63 from $60 at Wedbush
Wedbush raised the firm’s price target on Ideaya Biosciences (IDYA) to $63 from $60 and keeps an Outperform rating on the shares. The firm notes the company reported third quarter…
Ideaya Biosciences price target lowered to $52 from $57 at Guggenheim
Guggenheim lowered the firm’s price target on Ideaya Biosciences (IDYA) to $52 from $57 and keeps a Buy rating on the shares.
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu...
Ideaya Biosciences price target lowered to $57 from $59 at Truist
Truist lowered the firm’s price target on Ideaya Biosciences (IDYA) to $57 from $59 and keeps a Buy rating on the shares. The company’s Q3 and the firm’s 1×1 with…
Ideaya Biosciences reports Q3 EPS ($1.22), consensus ($1.16)
Reports Q3 revenue $10.24M, consensus $7.58M. “We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for…
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disea...
IDEAYA Biosciences Earnings release: Q3 2026
IDEAYA Biosciences released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
IDEAYA Biosciences Quarterly report: Q3 2026
IDEAYA Biosciences has published its Q3 2026 quarterly earnings report on November 3, 2026.
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization ...
Ideaya Biosciences price target lowered to $44 from $50 at Mizuho
Mizuho lowered the firm’s price target on Ideaya Biosciences (IDYA) to $44 from $50 and keeps an Outperform rating on the shares.
Ideaya Biosciences announces updated clinical results from IDE849 trial
Ideaya Biosciences (IDYA) announced updated clinical results that show anti-tumor activity and preliminary overall survival results for IDE849, its investigational antibody-drug conjugate, or ADC, dir...
IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas
17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5% (55...
Ideaya Biosciences presents updated data from three darovasertib studies
Ideaya Biosciences (IDYA) announced updated clinical data from three ongoing studies evaluating darovasertib in metastatic and primary uveal melanoma, or UM, that will be presented at the European Soc...
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of HLA-A*02:...
Ideaya Biosciences initiated with an Outperform at William Blair
William Blair initiated coverage of Ideaya Biosciences (IDYA) with an Outperform rating. The company is nearing its first potential approval for its lead product, darovasertib, in the first half of…
Ideaya Biosciences resumed with a Buy at Stifel
Stifel analyst Laura Prendergast resumed coverage of Ideaya Biosciences (IDYA) with a Buy rating and $48 price target The darovasertib plus crizotinib combo is set to become the standard of…
Ideaya Biosciences appoints Michael White as president, R&D
IDEAYA Biosciences (IDYA) announced the promotion of Dr. Michael White, from Chief Scientific Officer to President, Research and Development. White has served as CSO since 2021.
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
IDEAYA Biosciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A diversified precision oncology pipeline is advancing, with darovasertib nearing NDA submission and multiple phase III studies ongoing. DLL3 ADC and MTAP/KRAS programs target high unmet needs, supported by strategic collaborations and a data-driven approach to capital allocation. Key updates are expected at the upcoming R&D Day.
IDEAYA Biosciences Transcript: Citigroup’s Biopharma Back to School Summit 2026
Late-stage oncology assets are advancing, with NDA submission for darovasertib nearly complete and commercial launch expected next year. IDE849 is moving to phase III, and new data on multiple pipeline assets and AI-driven innovations will be presented at ESMO and an R&D Day in London.
IDEAYA Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Final NDA submission for darovasertib is imminent, with positive FDA feedback and new data to be presented at ESMO. The pipeline advances include a phase III DLL3 ADC trial in small cell lung cancer, strategic collaborations with Roche, and expansion into PRMT5 and CDKN2A programs.
Ideaya Biosciences price target raised to $57 from $54 at Guggenheim
Guggenheim raised the firm’s price target on Ideaya Biosciences (IDYA) to $57 from $54 and keeps a Buy rating on the shares while previewing upcoming data for IDE849 due in…